Quick Summary
- FDA denied Replimune’s RP1 melanoma immunotherapy approval for the second consecutive time
- The treatment was under evaluation for use with Bristol Myers Squibb’s (BMY) Opdivo
- FDA maintained its position that the clinical trial lacked adequate controls
- REPL shares plummeted approximately 19% to $4.76, with two volatility-triggered trading pauses
- Shares now trade significantly beneath the 52-week peak of $13.24
Replimune’s (REPL) experimental RP1 therapy has encountered its second regulatory roadblock from the FDA, as the agency maintains its position regarding inadequacies in the clinical trial framework supporting the marketing application.
The regulatory agency delivered a complete response letter rejecting approval for RP1, scientifically designated as vusolimogene oderparepvec, for combination therapy with Bristol Myers Squibb’s (BMY) Opdivo in treating advanced melanoma patients with prior anti-PD-1 exposure.
In correspondence directed to Kari Jeschke, Replimune’s senior vice president overseeing regulatory matters, the FDA stated that supplementary exploratory data analyses failed to change its previous determination. The agency found the RPL-001-16 clinical study did not meet standards for adequate and well-controlled investigations.
The FDA expressed no objections regarding safety profiles — the obstacle centers exclusively on demonstrating efficacy.
This marks the second regulatory denial. The initial rejection occurred in July 2025, following Vinay Prasad’s appointment two months prior to head the FDA’s Center for Biologics Evaluation and Research. Replimune resubmitted its Biologics License Application, gaining acceptance for reassessment in October 2025.
REPL shares declined roughly 19% to $4.76 following the announcement. Exchange officials implemented two trading suspensions throughout the session responding to extreme price swings. This pricing trajectory positions the stock toward its weakest closing level since October, based on Dow Jones Market Data.
At current levels, REPL trades substantially below its 52-week summit of $13.24.
Understanding RP1
RP1 represents a bioengineered variant of Herpes Simplex Virus type 1 — the viral strain responsible for oral cold sores. Replimune’s scientists redesigned it to selectively multiply within cancerous tissue, destroying malignant cells while simultaneously amplifying immune system activation through white blood cell engagement.
This therapy serves as the flagship asset within Replimune’s RPx platform, dedicated to developing oncolytic immunotherapy solutions targeting solid malignancies.
The biotechnology firm currently maintains a market capitalization approximating $393 million. No price-to-earnings ratio exists given negative earnings — a typical characteristic for clinical-stage biotechnology companies advancing therapeutic pipelines.
Corporate Transactions and Balance Sheet Metrics
Replimune’s GF Score registers at 40 on a 100-point scale, with profitability metrics scoring merely 1 out of 10. Financial stability achieves a 6 out of 10 rating.
During the preceding three-month period, company insiders disposed of $0.1 million in equity holdings, while no acquisitions were documented.
The equity currently changes hands at $4.76, markedly beneath the annual high of $13.24 established earlier this year.
